JP2001504876A - 新規化合物およびその使用方法 - Google Patents
新規化合物およびその使用方法Info
- Publication number
- JP2001504876A JP2001504876A JP52195898A JP52195898A JP2001504876A JP 2001504876 A JP2001504876 A JP 2001504876A JP 52195898 A JP52195898 A JP 52195898A JP 52195898 A JP52195898 A JP 52195898A JP 2001504876 A JP2001504876 A JP 2001504876A
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- group
- neuraminidase
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Materials Engineering (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. インフルエンザウイルスノイラミニダーゼの活性部位には結合するがノ イラミニダーゼによっては切断されない一種または2種以上の分子(ノイラミニ ダーゼバインダー)を結合した高分子化合物。 2. 高分子の骨格による立体障害をノイラミニダーゼバインーが受けないよ うにスペーサーもしくはリンカー基を介してノイラミニダーゼバインダーが上記 分子に結合してなる、請求項1記載の高分子化合物。 3. ノイラミニダーゼバインダーのIC50が10-6Mまたはこれより小さい 、請求項1または2記載の高分子化合物。 4. ノイラミニダーゼバインダーがシアリン酸誘導体である、請求項1から 3のいずれか1項に記載の高分子化合物。 5. シアリン酸化合物が、シアリン酸構造の7位を介して官能化された化合 物(I) である、請求項4記載の高分子化合物。 6. 次式(II): (X−Y)n−M−(Z)m (II) [式中、Xはスペーサー基Yを介して7位で高分子Mに連結しているノイラミニ ダーゼ結合2,3−デヒドロシアリン酸誘導体(2) であり、かつZは高分子上の任意の追加的置換基であり、 スペーサーYはW基に結合し、かつ Rはアジド基、非置換もしくは置換グアニジノ基、または非置換もしくは置換ア ミノ基を示し; R2はCOCH3、COCF3、SO2CH3またはSO2CF3を示し; WはO(C=O)NH、O(C=S)NH、NH(C=O)NHまたはNH(C =S)NHを表しかつNHを通じて基Yに結合しており; mは0から1000の整数であり;かつ nは1から1000の整数であり、このスペーサー基Yは炭素、窒素、酸素お よび硫黄から選択された1000原子までの、任意に置換された鎖であり; 高分子Mは共有結合もしくは非共有結合でスペーサー基Yに連結した、分子量1 04から107までの合成もしくは天然ポリマー、蛋白、抗体または酵素である] にて表される、請求項1から5のいずれか一項記載の高分子化合物。 7. 次式(IIA): (X’−Y)n−M−(Z)m (IIA) [式中、X’はエーテル側腕を通じて連結した式(2a) にて表されるノイラミニダーゼ結合シクロヘキセニル誘導体であり、 R、R2、Y、nおよびmは請求項6で定義したものであり、 R1およびW’は一種または2種以上のハロゲン原子もしくはアルコキシ、ハロ アルコキシまたは任意に置換されたアリール基により任意に置換された親油性C1 −C12アルキルもしくはアルキレン基である] にて表される、請求項1から3のいずれか1項に記載の高分子化合物。 8. Zが、血球凝集素を結合する基である、請求項6または7記載の高分子 化合物。 9. Zが、検出可能標識として作用し得る基である、請求項6または7記載 の高分子化合物。 10. Zが、ビオチンまたは蛍光分子である、請求項7記載の高分子化合物 。 11. Zが、検出アッセイに使用するのに適した酵素である、請求項6また は7記載の高分子化合物。 12. Zが、表面に上記高分子を結合させるのに適した末端官能性を有する 基である、請求項6または7記載の高分子化合物。 13. Zが、NH2、SH、CO2H、CHOまたはCH=CH2である、請 求項12記載の高分子化合物。 14. スペーサー基Yが、いずれも単独または組合せで使用可能なアミノア ルキル基、(ポリ)アミノ酸、直鎖ペプチド、オリゴ糖および多糖、ポリエチレ ングリコール単位、ならびにアミノジアルキル尿素からなる群から選択される、 請求項6から13のいずれか一項記載の高分子化合物。 15. Yが末端アミノ基を有する、請求項14記載の高分子化合物。 16. 高分子Mが、蛋白、酵素、抗体、水溶性合成ポリマー、多糖およびポ リミノ酸からなる群から選択される、請求項6から15のいずれか一項記載の高 分子化合物。 17. 高分子Mが、血清アルブミン(BSA)、セイヨウワサビペルオキシ ダーゼ(HRP)、アビジン、ストレプトアビジンまたはノイトロアビジン、お よび免疫グロブリンからなる群から選択される、請求項6から15のいずれか一 項記載の高分子化合物。 18. 高分子Mが多糖、ポリアクリルアミド、ポリエチレングリコール、ポ リ尿素、ポリ酸、ポリエステル、ポリアミドおよびN−(2−ヒドロキシ−プロ ピル)メタクリルアミド(HMPA)、からなる群から選択され、上記高分子が 医薬として容認し得るものである、請求項6から15のいずれか一項記載の高分 子化合物。 19. Rが、メチル、エチル、アリル、アミノ、シアノまたはニトロ基で置 換されたグアニジノまたはアミノ基である、請求項6から18のいずれか一項記 載の高分子化合物。 20. Xが式(2)の化合物であり、式中のRがグアニジンであり、R2が アセチルであり、Wが基O(=CO)NHであり、スペーサーYが6から60の 炭素、窒素および酸素原子からなる鎖である、請求項6記載の高分子化合物。 21. インフルエンザウイルスノイラミニダーゼの活性部位に特異的に結合 し得る、請求項1から20のいずれか一項記載の化合物に、インフルエンザウイ ルスを含むと疑がわれる試料を露出する工程を包含する、インフルエンザウイル スの検出方法。 22. 上記化合物が共有結合または非特異的結合により表面に結合し、かつ この場合のスペーサー基Yは、ノイラミニダーゼ結合単位Xが高分子Mの表面に さらされてウイルス粒子へと接近できるのに十分な長さを有する、請求項21記 載の方法。 23. 選択的捕獲アッセイ、選択的検出アッセイ、または選択的捕獲−選択 的検出の組み合わせアッセイである、請求項21または22記載の方法。 24. 本発明化合物、好ましくは請求項1から7、13、14および18か ら20のいずれか一項記載の化合物または医薬として容認できるそれらの誘導体 を、医薬として容認できる担体と共に含むインフルエンザAまたはインフルエン ザBの治療用組成物であって、ノイラミニダーゼに対するこの化合物のID50が 5μg/ml未満である組成物。 25. この化合物が請求項6または請求項7記載の化合物である、請求項2 4記載の組成物。 26. 一種または2種以上の追加的治療活性剤をさらに含む、請求項24ま たは25記載の組成物。 27. 追加的治療活性剤が抗ウイルス剤である、請求項26記載の組成物。 28. 本発明化合物、好ましくは請求項1から7、13、14および18か ら20のいずれか一項記載の化合物、または医薬として容認できるそれらの誘導 体の有効量を治療を必要とする哺乳類に投与する工程を包含する、ヒトを含めた 哺乳類におけるインフルエンザ感染の治療方法であって、ノイラミニダーゼに対 する上記化合物のID50が5μg/ml未満である治療方法。 29. インフルエンザウイルス感染の治療用医薬を製造するための、請求項 1から7、13、14および18から20のいずれか一項記載の化合物の使用で あって、この化合物のノイラミニダーゼに対するID50が5μg/ml未満であ る使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPO3632A AUPO363296A0 (en) | 1996-11-14 | 1996-11-14 | Method and novel compounds for use therein |
AUPO8539A AUPO853997A0 (en) | 1997-08-14 | 1997-08-14 | Method and novel compounds for use therein |
AU8539 | 1997-08-14 | ||
PCT/AU1997/000771 WO1998021243A1 (en) | 1996-11-14 | 1997-11-13 | Method and novel compounds for use therein |
AU3632 | 1999-10-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001504876A true JP2001504876A (ja) | 2001-04-10 |
JP3691075B2 JP3691075B2 (ja) | 2005-08-31 |
Family
ID=25645315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52195898A Expired - Fee Related JP3691075B2 (ja) | 1996-11-14 | 1997-11-13 | 新規化合物およびその使用方法 |
Country Status (19)
Country | Link |
---|---|
US (1) | US6680054B1 (ja) |
EP (1) | EP0951480A4 (ja) |
JP (1) | JP3691075B2 (ja) |
KR (1) | KR20000068986A (ja) |
CN (1) | CN1238783A (ja) |
AP (1) | AP9901531A0 (ja) |
AU (1) | AU732916C (ja) |
BR (1) | BR9714299A (ja) |
CA (1) | CA2271249C (ja) |
CZ (1) | CZ167999A3 (ja) |
EA (1) | EA001603B1 (ja) |
HU (1) | HUP9904009A3 (ja) |
IL (1) | IL129762A0 (ja) |
IS (1) | IS5044A (ja) |
NO (1) | NO992297L (ja) |
NZ (1) | NZ335368A (ja) |
PL (1) | PL333364A1 (ja) |
TR (1) | TR199901081T2 (ja) |
WO (1) | WO1998021243A1 (ja) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6518305B1 (en) | 1998-04-23 | 2003-02-11 | Abbott Laboratories | Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases |
US6455571B1 (en) | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
US7425541B2 (en) * | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
AUPP913999A0 (en) | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
US6593314B1 (en) | 1999-10-19 | 2003-07-15 | Abbott Laboratories | Neuraminidase inhibitors |
GB0015324D0 (en) * | 2000-06-22 | 2000-08-16 | Biota Scient Management | Medicaments |
AUPR001000A0 (en) * | 2000-09-08 | 2000-10-05 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
US20030068655A1 (en) * | 2001-09-12 | 2003-04-10 | Protiveris, Inc. | Microcantilever apparatus and methods for detection of enzymes |
AUPR879401A0 (en) | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
WO2006090119A1 (en) * | 2005-02-23 | 2006-08-31 | Lipoxen Technologies Limited | Activated sialic acid derivatives for protein derivatisation and conjugation |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
ES2581381T3 (es) * | 2007-06-25 | 2016-09-05 | Autoimmune Technologies, Llc | Composiciones y métodos de inhibición de la gripe |
AU2008272792B2 (en) | 2007-07-03 | 2014-03-06 | Children's Hospital & Research Center At Oakland | Oligosialic acid derivatives, methods of manufacture, and immunological uses |
CA2692417C (en) | 2007-07-03 | 2017-03-21 | Children's Hospital & Research Center At Oakland | Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting |
US8999954B2 (en) * | 2007-07-03 | 2015-04-07 | Childern's Hospital & Research Center at Oakland | Inhibitors of polysialic acid de-N-acetylase and methods for using the same |
US20130280204A1 (en) * | 2007-08-27 | 2013-10-24 | Massachusetts Institute Of Technology | Polymer-Attached Inhibitors of Influenza Virus |
US20090076133A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched zanamivir |
US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
AU2010247141A1 (en) | 2009-05-15 | 2011-12-15 | Redx Pharma Plc | Redox drug derivatives |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
PL225045B1 (pl) | 2012-05-18 | 2017-02-28 | Univ Jagielloński | Zastosowanie polimeru chitozanowego do wytwarzania leków do leczenia i profilaktyki infekcji wywołanych przez koronawirusy |
CA2880701A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
WO2014152946A2 (en) | 2013-03-14 | 2014-09-25 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
AU2014248225B2 (en) | 2013-04-01 | 2020-06-25 | Becton, Dickinson And Company | Methods and kits for the diagnosis of influenza |
WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2015109180A2 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
JP6562942B2 (ja) | 2014-03-27 | 2019-08-28 | アカデミア シニカAcademia Sinica | 反応性標識化合物およびその使用 |
AU2015267047A1 (en) | 2014-05-27 | 2017-01-05 | Academia Sinica | Anti-CD20 glycoantibodies and uses thereof |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
TWI654202B (zh) | 2014-05-27 | 2019-03-21 | 中央研究院 | 增進抗體功效之通用糖型之組合物及方法 |
CA2950440A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
AU2015267044A1 (en) | 2014-05-28 | 2016-12-15 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
CA2960712A1 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | Human inkt cell activation using glycolipids |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
WO2016118191A1 (en) | 2015-01-24 | 2016-07-28 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
CA3005774C (en) | 2015-11-20 | 2024-01-09 | Australian Biomedical Co. Pty Ltd | Compounds and methods for the treatment and/or prevention of influenza infection |
CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
EP3500594A4 (en) | 2016-08-22 | 2020-03-11 | Cho Pharma Inc. | ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE |
CN113194983A (zh) | 2018-09-06 | 2021-07-30 | 奇达拉治疗公司 | 用于治疗病毒感染的组合物及方法 |
TW202122117A (zh) | 2019-09-06 | 2021-06-16 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ288492B6 (en) | 1990-04-24 | 2001-06-13 | Biota Scient Management | Derivatives of alpha-D-neuraminic acid, process of their preparation, their use and pharmaceutical preparations based thereon |
US5221611A (en) | 1991-06-19 | 1993-06-22 | Sigma Chemical Company | Ddi immunoassays, derivatives, conjugates and antibodies |
CA2081068C (en) * | 1991-10-23 | 2005-11-29 | Laurence Mark Von Itzstein | Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of .alpha.-d-neuraminic acid |
WO1994011005A1 (en) * | 1992-11-09 | 1994-05-26 | Scientific Dimensions Usa, Inc. | Viral attachment inhibitors |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
GB9410817D0 (en) | 1994-05-28 | 1994-07-20 | Glaxo Group Ltd | Medicaments |
DE759917T1 (de) * | 1995-02-27 | 1998-10-22 | Gilead Sciences Inc | Neue selektive inhibitoren viraler oder bakterieller neuraminidasen |
GB9516276D0 (en) | 1995-08-08 | 1995-10-11 | Biota Scient Management | Chemical compounds |
ATE238552T1 (de) | 1996-03-01 | 2003-05-15 | Biota Scient Management | Verfahren zum nachweis von influenza-virus und dazu verwendbare verbindungen |
AUPO104396A0 (en) | 1996-07-17 | 1996-08-08 | Biomolecular Research Institute Limited | Antiviral linear polymers |
AUPP913999A0 (en) * | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
-
1997
- 1997-11-13 TR TR1999/01081T patent/TR199901081T2/xx unknown
- 1997-11-13 WO PCT/AU1997/000771 patent/WO1998021243A1/en not_active Application Discontinuation
- 1997-11-13 AU AU48576/97A patent/AU732916C/en not_active Ceased
- 1997-11-13 EP EP97911065A patent/EP0951480A4/en not_active Withdrawn
- 1997-11-13 AP APAP/P/1999/001531A patent/AP9901531A0/en unknown
- 1997-11-13 BR BR9714299-9A patent/BR9714299A/pt not_active Application Discontinuation
- 1997-11-13 IL IL12976297A patent/IL129762A0/xx unknown
- 1997-11-13 EA EA199900459A patent/EA001603B1/ru not_active IP Right Cessation
- 1997-11-13 CA CA2271249A patent/CA2271249C/en not_active Expired - Fee Related
- 1997-11-13 CZ CZ991679A patent/CZ167999A3/cs unknown
- 1997-11-13 NZ NZ335368A patent/NZ335368A/en unknown
- 1997-11-13 CN CN97199728A patent/CN1238783A/zh active Pending
- 1997-11-13 US US09/308,076 patent/US6680054B1/en not_active Expired - Fee Related
- 1997-11-13 JP JP52195898A patent/JP3691075B2/ja not_active Expired - Fee Related
- 1997-11-13 HU HU9904009A patent/HUP9904009A3/hu unknown
- 1997-11-13 KR KR1019997004301A patent/KR20000068986A/ko not_active Application Discontinuation
- 1997-11-13 PL PL97333364A patent/PL333364A1/xx unknown
-
1999
- 1999-04-30 IS IS5044A patent/IS5044A/is unknown
- 1999-05-12 NO NO992297A patent/NO992297L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0951480A1 (en) | 1999-10-27 |
KR20000068986A (ko) | 2000-11-25 |
IS5044A (is) | 1999-04-30 |
CA2271249C (en) | 2010-07-20 |
NZ335368A (en) | 2001-08-31 |
CN1238783A (zh) | 1999-12-15 |
EA199900459A1 (ru) | 1999-12-29 |
IL129762A0 (en) | 2000-02-29 |
EA001603B1 (ru) | 2001-06-25 |
US6680054B1 (en) | 2004-01-20 |
EP0951480A4 (en) | 2004-07-28 |
AU732916B2 (en) | 2001-05-03 |
CA2271249A1 (en) | 1998-05-22 |
NO992297D0 (no) | 1999-05-12 |
PL333364A1 (en) | 1999-12-06 |
JP3691075B2 (ja) | 2005-08-31 |
WO1998021243A1 (en) | 1998-05-22 |
AP9901531A0 (en) | 1999-05-13 |
AU732916C (en) | 2002-06-06 |
AU4857697A (en) | 1998-06-03 |
HUP9904009A3 (en) | 2001-07-30 |
HUP9904009A2 (hu) | 2000-03-28 |
TR199901081T2 (xx) | 1999-08-23 |
CZ167999A3 (cs) | 1999-10-13 |
BR9714299A (pt) | 2000-04-25 |
NO992297L (no) | 1999-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3691075B2 (ja) | 新規化合物およびその使用方法 | |
Sigal et al. | Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: the strong inhibition reflects enhanced binding through cooperative polyvalent interactions | |
US6949524B2 (en) | Polysaccharide conjugates of biomolecules | |
AU2005299536B2 (en) | Immunoassays for topiramate | |
JP4576429B2 (ja) | タキソールの免疫学的検定 | |
US20060216767A1 (en) | Docetaxel immunoassay | |
JP2005097320A (ja) | 増強循環エフェクター組成物および方法 | |
JP2000514795A (ja) | トロンビンインヒビター及びエンドジーンキャリアの複合体 | |
CN102105191A (zh) | 可生物降解的金属螯合聚合物和疫苗 | |
US20060088933A1 (en) | Reagents for detecting efavirenz | |
CN107091826B (zh) | 一种基于痕量荧光免疫定量检测PSI-OAm-NAPI两亲聚合纳米药物载体的方法 | |
US20050282884A1 (en) | N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use | |
ITMI961309A1 (it) | Frammenti f(ab')2 e relative immunoglobuline igg, attivi come anticorpi specifici verso farmaci e i loro metaboliti, e loro | |
US7294615B1 (en) | Compounds that associate on the intermolecular level and aggregate bodies that contain them | |
JPH09507841A (ja) | プロカインアミドおよびnapaのマレイミド付加物結合体 | |
US4415552A (en) | Composition for establishing immunological tolerance | |
CN111939256B (zh) | 一种具有细菌调理特性的抗菌辅助材料及其制备方法和应用 | |
MXPA99004511A (en) | Method and novel compounds for use therein | |
JPH09511067A (ja) | 免疫酵素的コンジュゲート、その製造方法およびその使用 | |
CN110568184A (zh) | 一种负载抗癌药物喜树碱的纳米药物载体的荧光免疫定量检测方法 | |
JP3399598B2 (ja) | N−部分置換アミノグリカンを用いた免疫測定用標識試薬 | |
EP1542012B1 (en) | Antibodies for detecting efavirenz | |
CN118047886A (zh) | 化合物及其制备方法和封闭剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050328 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050517 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050615 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080624 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090624 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100624 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110624 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110624 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120624 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120624 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130624 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |